Italia - italiano - myHealthbox

bayer - acido acetilsalicilico - compresse gastroresistenti - 100mg - antitrombotico - cardioaspirin è un antitrombotico, cioè un medicinale che previene la formazione di coaguli di sangue (trombi) nei vasi sanguigni.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

ibsa farmaceutici italia s.r.l. - acido acetilsalicilico - acido acetilsalicilico

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

bayer s.p.a. - acido acetilsalicilico, ass. escl. psicolettici - acido acetilsalicilico, ass. escl. psicolettici

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - acidum acetylsalicylicum - compresse rivestite con film - acidum acetylsalicylicum 100 mg, cellulosi pulvis, maydis amylum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.005 mg, polysorbatum 80, talcum, triethylis citras, pro compresso obducto. - thrombozytenaggregationshemmung: reinfarktprophylaxe, reokklusionsprophylaxe, instabile angina pectoris - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - acidum acetylsalicylicum - compresse rivestite con film - acidum acetylsalicylicum 300 mg, cellulosi pulvis, maydis amylum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.01 mg, polysorbatum 80, talcum, triethylis citras, pro compresso obducto. - thrombozytenaggregationshemmung: reinfarktprophylaxe, reokklusionsprophylaxe, instabile angina pectoris - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - acidum acetylsalicylicum - compresse rivestite con film - acidum acetylsalicylicum 100 mg, cellulosum microcristallinum, maydis amylum, silica colloidalis anhydrica, acidum stearicum, Überzug: acidi methacrylici et ethylis acrylatis polymerisatum 1:1, polysorbatum 80, natrii laurilsulfas corresp. natrium 2 µg, triethylis citras, talcum pro compresso obducto. - thrombozytenaggregationshemmung: reinfarktprophylaxe, reokklusionsprophylaxe, instabile angina pectoris - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - acidum acetylsalicylicum, pseudoephedrini hydrochloridum - granulat - acidum acetylsalicylicum 500 mg, pseudoephedrini hydrochloridum 30 mg, acidum citricum, saccharum 2000 mg, hypromellosum, saccharinum, aromatica (orange) cum alcohol benzylicus 3.84 mg et maltodextrinum et aurantii dulcis aetheroleum, ad granulatum, pro charta. - raffreddore con erkältungsbedingten il dolore e la febbre - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

adamed s.r.l. - rosuvastatina e acido acetilsalicilico - rosuvastatina e acido acetilsalicilico

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - agenti antitrombotici - prevenzione del tromboembolismo venoso (tev) in pazienti adulti sottoposti a chirurgia sostitutiva elettiva dell'anca o del ginocchio. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 per haemodynamically instabile pe pazienti). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 e 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Unione Europea - italiano - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agenti antitrombotici - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.